NCT00012376View on ClinicalTrials.gov

Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

March 31, 2001

Primary Completion Date

January 31, 2010

Conditions
Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Blastic Phase Chronic Myelogenous LeukemiaChronic Myelomonocytic LeukemiaChronic Phase Chronic Myelogenous LeukemiaParoxysmal Nocturnal HemoglobinuriaPreviously Treated Myelodysplastic SyndromesRecurrent Adult Acute Myeloid LeukemiaRefractory AnemiaRefractory Anemia With Ringed SideroblastsRelapsing Chronic Myelogenous LeukemiaThrombocytopeniaUntreated Adult Acute Myeloid Leukemia
Interventions
DRUG

bryostatin 1

Given IV

BIOLOGICAL

sargramostim

Given subcutaneously

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

Trial Locations (1)

21287-8936

Johns Hopkins University, Baltimore

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00012376 - Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer | Biotech Hunter | Biotech Hunter